Oppenheimer upbeat on Veru, says 'come for the lean mass, stay for the muscle function'
VERU•Oppenheimer rated Veru “outperform” with a $24 price target, citing confidence that interim results next quarter will show enobosarm preserves lean body mass and increases fat loss versus semaglutide alone. Veru shares last closed at $2.19, up 2.3% year to date.
1. Analyst view and trial
Oppenheimer said it has high confidence that Veru’s experimental oral drug enobosarm will show significant lean body mass preservation and greater fat loss than semaglutide alone in a mid-stage interim analysis next quarter. The brokerage said consistent gains in lean muscle mass and reductions in fat mass would support enobosarm’s long-term use alongside GLP-1 weight-loss drugs and could reduce risk ahead of a fourth-quarter 2027 topline readout.
